Nutriband (NASDAQ:NTRB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Nutriband (NASDAQ:NTRB) to a hold rating in a report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nutriband in a report on Monday, September 28th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Nutriband Stock Performance

NASDAQ:NTRB opened at $6.00 on Friday. Nutriband has a 52 week low of $2.80 and a 52 week high of $9.19. The firm has a market cap of $72.96 million, a price-to-earnings ratio of -11.32 and a beta of 1.92. The firm’s 50-day simple moving average is $5.92 and its 200 day simple moving average is $4.30.

Nutriband (NASDAQ:NTRB) last posted its quarterly earnings data on Friday, September 4th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.44 million during the quarter. Nutriband had a negative net margin of 430.35% and a negative return on equity of 109.07%.

About Nutriband

Nutriband Inc (NASDAQ:NTRB) develops and manufactures transdermal patches and other wearable drug-delivery products for pharmaceutical, over-the-counter, consumer, and wellness markets. The company’s capabilities include product development, formulation, manufacturing, packaging, and private-label services for customers seeking patch-based delivery systems.

Nutriband’s portfolio includes consumer and wellness patches, as well as prescription-focused transdermal technologies. Its AVERSA platform is designed to incorporate abuse-deterrent features into transdermal products, with the goal of helping reduce the risk of drug extraction, misuse, or abuse.